How a Supreme Court ruling could mean headaches for the drug industry

The overturning of the Chevron doctrine could lead to the one thing the biopharma industry hates more than a bad policy: uncertainty.

July 2, 2024 Check out STAT+

Sponsored By

Alex Wong/Getty Images STAT+ | Supreme Court's gutting of Chevron doctrine could mean headaches for drug industry The weakening of the FDA's regulatory powers may lead to the one thing industry hates more than bad policy: uncertainty. By Nicholas Florko, Lizzy Lawrence, John Wilkerson, and Elaine Chen STAT+ | The biotech scorecard for the third quarter: 19 stock-moving events to watch Events to watch will include data on a Novo Nordisk obesity drug and an FDA advisory panel hearing on AstraZeneca's checkpoint inhibitor Imfinzi. By Adam Feuerstein STAT+ | Medicare's big experiment to fix kidney failure care hasn't worked so far, studies say Years of financial incentives haven't resulted in moving appreciably more kidney failure patients to home dialysis. By Isabella Cueto

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser